Almanric Karine, Marceau Nathalie, Cantin Ariane, Bertin Émilie
BPharm, MSc, BCOP, is a Pharmacist with the Hôpital de la Cité-de-la-Santé (CISSS de Laval), Laval, Quebec.
BPharm, MSc, is a Pharmacist with the Hôpital de la Cité-de-la-Santé (CISSS de Laval), Laval, Quebec.
Can J Hosp Pharm. 2017 Mar-Apr;70(2):99-106. doi: 10.4212/cjhp.v70i2.1641. Epub 2017 Apr 28.
Cisplatin-induced nephrotoxicity occurs in about one-third of patients who receive this chemotherapy drug. In late 2012, the study institution began measuring serum creatinine on day 7 after administration of cisplatin to identify patients with acute renal failure.
To evaluate the extent of nephrotoxicity associated with cisplatin and the influence of risk factors for nephrotoxicity.
This retrospective study involved patients who received a first cycle of cisplatin-based chemotherapy between November 1, 2012, and November 1, 2013. Patients' medical records were reviewed to determine the increase in creatinine level (graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events) and the influence of certain prespecified risk factors, such as age, concomitant medications, initial dose of cisplatin, and related medical conditions.
Among the 80 patients evaluated, 14 (17%) experienced no increase in the level of serum creatinine (grade 0), 44 (55%) experienced a grade 1 increase, 19 (24%) a grade 2 increase, and 3 (4%) a grade 3 increase; no patients experienced a grade 4 increase. Patients with the greatest risk of a grade 2 or 3 increase were those treated with hydrochlorothiazide (odds ratio [OR] 9.35, 95% confidence interval [CI] 2.49 to 35.14) or an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker (OR 5.02, 95% CI 1.76 to 14.32). After adjustment, only hydrochlorothiazide was associated with an increased risk of nephrotoxicity (OR 5.39, 95% CI 1.04 to 28.07). Among patients taking hydrochlorothiazide, the average incremental increase in serum creatinine was 59.9 μmol/L (95% CI 34.3 to 85.4 μmol/L).
Taking hydrochlorothiazide was associated with a significant increase in serum creatinine following cisplatin therapy. On the basis of these results, patients should stop taking hydrochlorothiazide before undergoing cisplatin-based chemotherapy.
接受顺铂这种化疗药物治疗的患者中,约三分之一会发生顺铂诱导的肾毒性。2012年末,研究机构开始在顺铂给药后第7天测定血清肌酐,以识别急性肾衰竭患者。
评估与顺铂相关的肾毒性程度以及肾毒性危险因素的影响。
这项回顾性研究纳入了2012年11月1日至2013年11月1日期间接受首个基于顺铂化疗周期的患者。查阅患者的病历,以确定肌酐水平的升高情况(根据美国国立癌症研究所不良事件通用术语标准分级)以及某些预先指定的危险因素的影响,如年龄、伴随用药、顺铂初始剂量和相关疾病状况。
在评估的80例患者中,14例(17%)血清肌酐水平未升高(0级),44例(55%)肌酐水平升高1级,19例(24%)升高2级,3例(4%)升高3级;无患者肌酐水平升高4级。发生2级或3级升高风险最高的患者是接受氢氯噻嗪治疗的患者(比值比[OR] 9.35,95%置信区间[CI] 2.49至35.14)或接受血管紧张素转换酶抑制剂或血管紧张素II受体阻滞剂治疗的患者(OR 5.02,95% CI 1.76至14.32)。调整后,只有氢氯噻嗪与肾毒性风险增加相关(OR 5.39,95% CI 1.04至28.07)。在服用氢氯噻嗪的患者中,血清肌酐的平均增量为59.9 μmol/L(95% CI 34.3至85.4 μmol/L)。
服用氢氯噻嗪与顺铂治疗后血清肌酐显著升高相关。基于这些结果,患者在接受基于顺铂的化疗前应停用氢氯噻嗪。